JP7620803B2 - 組織特異的メチル化マーカー - Google Patents

組織特異的メチル化マーカー Download PDF

Info

Publication number
JP7620803B2
JP7620803B2 JP2020548776A JP2020548776A JP7620803B2 JP 7620803 B2 JP7620803 B2 JP 7620803B2 JP 2020548776 A JP2020548776 A JP 2020548776A JP 2020548776 A JP2020548776 A JP 2020548776A JP 7620803 B2 JP7620803 B2 JP 7620803B2
Authority
JP
Japan
Prior art keywords
cancer
tissue
methylation
target sequence
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020548776A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019178496A5 (https=
JP2021518107A (ja
JP2021518107A5 (https=
Inventor
ロ，ユク－ミン，デニス
クン チウ，ロッサ，ワイ
チャン，クワン，チー
ガイ，ワンシァ
ジ，ルー
Original Assignee
グレイル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グレイル インコーポレイテッド filed Critical グレイル インコーポレイテッド
Publication of JP2021518107A publication Critical patent/JP2021518107A/ja
Publication of JPWO2019178496A5 publication Critical patent/JPWO2019178496A5/ja
Publication of JP2021518107A5 publication Critical patent/JP2021518107A5/ja
Priority to JP2024109900A priority Critical patent/JP2024156679A/ja
Application granted granted Critical
Publication of JP7620803B2 publication Critical patent/JP7620803B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6823—Release of bound markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020548776A 2018-03-15 2019-03-15 組織特異的メチル化マーカー Active JP7620803B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024109900A JP2024156679A (ja) 2018-03-15 2024-07-08 組織特異的メチル化マーカー

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862643649P 2018-03-15 2018-03-15
US62/643,649 2018-03-15
US201862769928P 2018-11-20 2018-11-20
US62/769,928 2018-11-20
PCT/US2019/022504 WO2019178496A1 (en) 2018-03-15 2019-03-15 Tissue-specific methylation marker

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024109900A Division JP2024156679A (ja) 2018-03-15 2024-07-08 組織特異的メチル化マーカー

Publications (4)

Publication Number Publication Date
JP2021518107A JP2021518107A (ja) 2021-08-02
JPWO2019178496A5 JPWO2019178496A5 (https=) 2022-03-22
JP2021518107A5 JP2021518107A5 (https=) 2022-03-22
JP7620803B2 true JP7620803B2 (ja) 2025-01-24

Family

ID=67908065

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020548776A Active JP7620803B2 (ja) 2018-03-15 2019-03-15 組織特異的メチル化マーカー
JP2024109900A Pending JP2024156679A (ja) 2018-03-15 2024-07-08 組織特異的メチル化マーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024109900A Pending JP2024156679A (ja) 2018-03-15 2024-07-08 組織特異的メチル化マーカー

Country Status (11)

Country Link
US (2) US11884966B2 (https=)
EP (1) EP3766076A4 (https=)
JP (2) JP7620803B2 (https=)
CN (2) CN112534506B (https=)
AU (1) AU2019233897B2 (https=)
CA (1) CA3093971A1 (https=)
IL (1) IL277306A (https=)
PH (1) PH12020551712A1 (https=)
SG (1) SG11202008957VA (https=)
TW (1) TWI848941B (https=)
WO (1) WO2019178496A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7620803B2 (ja) 2018-03-15 2025-01-24 グレイル インコーポレイテッド 組織特異的メチル化マーカー
KR102155044B1 (ko) * 2019-10-08 2020-09-11 주식회사 레피다인 생물학적 시료의 간암 조직 기원 여부를 판별하는 방법
KR102103885B1 (ko) * 2019-10-08 2020-04-24 주식회사 레피다인 생물학적 시료의 간 조직 유래 여부를 판별하는 방법
JP2023516525A (ja) * 2019-12-26 2023-04-20 広州市基准医療有限公司 Ｄｎａメチル化バイオマーカーの組み合わせ、検出方法および試薬キット
GB2612447B (en) * 2020-04-24 2025-08-13 Univ Cornell Methods for detecting tissue damage, graft versus host disease, and infections using cell-free DNA profiling
EP4291677A2 (en) 2021-02-09 2023-12-20 F. Hoffmann-La Roche AG Methods for base-level detection of methylation in nucleic acids
WO2023144704A1 (en) * 2022-01-25 2023-08-03 Gene Solutions Joint Stock Company Systems and methods for detecting tumor dna in mammalian blood
EP4540408A1 (en) 2022-06-14 2025-04-23 F. Hoffmann-La Roche AG Detection of epigenetic cytosine modification
WO2024112741A1 (en) * 2022-11-23 2024-05-30 Salk Institute For Biological Studies Dna methylation barcodes for identifying brain cells
CN117476222B (zh) * 2023-09-28 2024-10-25 上海交通大学医学院附属瑞金医院 一种肠癌肝转移的风险预测方法、系统和电子设备

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536639A (ja) 2012-09-20 2015-12-24 ザ チャイニーズ ユニバーシティ オブ ホンコン 血漿による胎児または腫瘍のメチロームの非侵襲的決定
US20160017419A1 (en) 2014-07-18 2016-01-21 The Chinese University Of Hong Kong Methylation pattern analysis of tissues in a dna mixture
JP2017514499A (ja) 2014-05-09 2017-06-08 ライフコーデックス アーゲー 特別な細胞タイプに由来するｄｎａの検出とそれに関連する方法
JP2017516504A (ja) 2014-06-04 2017-06-22 クエスト ダイアグノスティクス インベストメンツ インコーポレイテッド 結腸直腸癌のためのメチル化マーカー
WO2017129716A1 (en) 2016-01-29 2017-08-03 Epigenomics Ag Methods for detecting cpg methylation of tumor-derived dna in blood samples
WO2017212428A1 (en) 2016-06-07 2017-12-14 The Regents Of The University Of California Cell-free dna methylation patterns for disease and condition analysis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX349568B (es) 2010-11-30 2017-08-03 Univ Hong Kong Chinese Deteccion de aberraciones geneticas o moleculares asociadas con el cancer.
US9732390B2 (en) * 2012-09-20 2017-08-15 The Chinese University Of Hong Kong Non-invasive determination of methylome of fetus or tumor from plasma
CN106232833A (zh) 2014-01-30 2016-12-14 加利福尼亚大学董事会 用于非侵入性诊断的甲基化单体型分析(monod)
EP3132055A2 (en) * 2014-04-14 2017-02-22 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. A method and kit for determining the tissue or cell origin of dna
EP2942400A1 (en) * 2014-05-09 2015-11-11 Lifecodexx AG Multiplex detection of DNA that originates from a specific cell-type
ES2879964T3 (es) * 2014-12-12 2021-11-23 Exact Sciences Dev Co Llc Composiciones y métodos para realizar ensayos de detección de metilación
JP7620803B2 (ja) 2018-03-15 2025-01-24 グレイル インコーポレイテッド 組織特異的メチル化マーカー

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536639A (ja) 2012-09-20 2015-12-24 ザ チャイニーズ ユニバーシティ オブ ホンコン 血漿による胎児または腫瘍のメチロームの非侵襲的決定
JP2017514499A (ja) 2014-05-09 2017-06-08 ライフコーデックス アーゲー 特別な細胞タイプに由来するｄｎａの検出とそれに関連する方法
JP2017516504A (ja) 2014-06-04 2017-06-22 クエスト ダイアグノスティクス インベストメンツ インコーポレイテッド 結腸直腸癌のためのメチル化マーカー
US20160017419A1 (en) 2014-07-18 2016-01-21 The Chinese University Of Hong Kong Methylation pattern analysis of tissues in a dna mixture
WO2017129716A1 (en) 2016-01-29 2017-08-03 Epigenomics Ag Methods for detecting cpg methylation of tumor-derived dna in blood samples
WO2017212428A1 (en) 2016-06-07 2017-12-14 The Regents Of The University Of California Cell-free dna methylation patterns for disease and condition analysis

Also Published As

Publication number Publication date
IL277306A (en) 2020-10-29
JP2024156679A (ja) 2024-11-06
WO2019178496A1 (en) 2019-09-19
CA3093971A1 (en) 2019-09-19
SG11202008957VA (en) 2020-10-29
TWI848941B (zh) 2024-07-21
EP3766076A1 (en) 2021-01-20
KR20210023804A (ko) 2021-03-04
EP3766076A4 (en) 2021-12-29
US20190390257A1 (en) 2019-12-26
JP2021518107A (ja) 2021-08-02
AU2019233897A1 (en) 2020-10-22
US20240191282A1 (en) 2024-06-13
TW202010845A (zh) 2020-03-16
CN119955906A (zh) 2025-05-09
AU2019233897B2 (en) 2024-10-24
PH12020551712A1 (en) 2021-06-21
CN112534506A (zh) 2021-03-19
US11884966B2 (en) 2024-01-30
CN112534506B (zh) 2025-03-04

Similar Documents

Publication Publication Date Title
JP7620803B2 (ja) 組織特異的メチル化マーカー
JP7513653B2 (ja) 無細胞ｄｎａについての体細胞起源または生殖系列起源の識別
TWI797095B (zh) 腫瘤檢測之方法及系統
CN115667554A (zh) 通过核酸甲基化分析检测结直肠癌的方法和系统
US11211147B2 (en) Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
JP2023500386A (ja) 大腸がんおよび／または進行性腺腫の検出
JP2018514187A (ja) 発現レベルおよび配列変種情報を用いて疾患の発症または再発のリスクを評価するための方法
US20230002831A1 (en) Methods and compositions for analyses of cancer
WO2024124207A2 (en) Systems and methods for cell-free nucleic acids methylation assessment
Zhang et al. Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets
Brannon et al. Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assay
EP4629247A1 (en) Methods and systems for tumor informed circulating tumor fraction estimation
US20250259702A1 (en) Methods and systems for determining blood tumor mutational burden in a liquid biopsy assay
KR102954537B1 (ko) 조직 특이적 메틸화 마커
HK40042779B (zh) 组织特异性的甲基化标志物
HK40042779A (en) Tissue-specific methylation marker
US20250137063A1 (en) Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
WO2025179073A1 (en) Methods and systems for tissue informed differentially methylated region analysis
Cheruba Development of a Novel Non-Invasive Cancer Detection Method Through Enrichment of CpG-Rich Regions in Cell-Free DNA
JP2025535077A (ja) 癌の多数の分析物検出のためのシステムおよび方法
Nikolaidis DNA methylation-assisted diagnosis of lung cancer in bronchial washings

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220311

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230501

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20230501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241218

R150 Certificate of patent or registration of utility model

Ref document number: 7620803

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150